Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$161.52+0.73 (+0.45%)
Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –
Novartis Core Operating Income: $21,889M in FY2025, up 12.3% from a year earlier.
Latest, FY2025
21,889
Period ended Dec 31, 2025
Change on a year earlier
+12.3%
19,494 in FY2024
History
2 years
Since FY2024
Sources
1
Novartis Form 6-K (0001114448-26-000007)
Where the FY2025 figure comes from
“|| Core operating income | 4 929 | 4 859 | 1 | 1 | 21 889 | 19 494 | 12 | 14”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K (Non-IFRS disclosures) & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Core Operating Income ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 21,889 | +12.3% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 19,494 | – | Novartis Form 6-K (0001114448-26-000007) ↗ |
Breakdown
What makes up core Operating Income
- Core Operating Income Growth at Constant Currencies (% cc)–
- Core Operating Income Growth in USD (% USD)–
- Currency Impact on Core Operating Income Growth (percentage points)–
- Core Operating Income Margin (%)40.1% · FY2025
- IFRS Operating Income Margin (%)32.4% · FY2025
- Core Gross Profit45,515 · FY2025
- Core Cost of Goods Sold-10,815 · FY2025
- Core R&D-10,295 · FY2025
- Core SG&A-13,238 · FY2025
- Core Income Before Taxes20,777 · FY2025
- Core Income Taxes-3,366 · FY2025
- Core Net Income17,411 · FY2025
- Core EPS (USD/share)8.98 · FY2025
Cite this data
StockData. (2026). Novartis Core Operating Income ($M), annual FY2024–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/core-operating-income
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.